Latest Conference Articles

Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.

Patients with early VA-ECMO use saw comparable outcomes to those who initially received conservative therapy for hemodynamic stabilization.

Education and place of birth contribute the most to the racial and ethnic differences observed in mean CVH score.

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

A single intravenous dose of NTLA-2001 significantly reduced abnormal levels of transthyretin in patients with ATTR amyloid cardiomyopathy, reports new data from AHA 2022.

Low sodium intake is considered less than 2.3 grams per day.

Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.

The late-breaking findings presented at AHA 2022 suggest the incidence of CV events was not lower among patients who received pemafibrate compared with those who received placebo.

In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.

National deaths from heart disease spiked in 2020 in the beginning of the COVID-19 pandemic, after an observed steady decline from 2010 to 2019.

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.

Only 12% of people with CVD older than age 65 used wearable devices, despite estimates suggesting half of all people with CVD are older than age 65.

The 30-year analysis suggests a significantly higher risk associated with lead exposure and lower risk for particulate matter in the US than in the UK.

There are plans for a larger sized study testing zetomipzomib in patients with lupus nephritis.

In a late-breaking abstract, investigators observed a 28% reduction in kidney disease progression or cardiovascular deaths compared to placebo.

With the population aging, there is a need for more home environmental treatment options for patients with kidney disease.

New research presented at Kidney Week 2022 ASN Annual Meeting, demonstrates an association between albuminuria and risk of cognitive problems.

A significantly higher number of patients receiving voclosporin achieved good renal outcome when compared with placebo.

In a late-breaking abstract, investigators assess how pantoprazole 40 mg daily effects long-term kidney function.

In a late-breaking abstract, investigators assess how discontinuation of ACEi or ARBs impact disease progression for advanced CKD.

The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.

In the last 20 years, most were adult studies which indicates a need for pediatric research activity, especially considering the potential that targeted therapies have for treating chronic kidney disease in children.

Approximately 1 out of every 6 patients with COVID-19 had a reduced eGFR.

Females generally have a lower risk of cardiovascular disease compared to males.

Data presented during ASN 2022 shows how heart failure impacts risk factors for renal outcomes of patients with chronic kidney disease.

New phase 3 data shared at Fall Clinical Dermatology show the IL-13 inhibitor maintained skin clearance observed at 16 weeks.

After the announced recall of dry shampoo products by Unilever this month, dermatologists anticipate an uptick in patient concerns.

Up to 2% of patients with IBD also have EoE.

Guselkumab bested placebo in clinical results of patients with ulcerative colitis.

"The best test is the 1 that gets done," Williams said.